Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Class A Common Stock, $0.001 par value per share
-
Shares outstanding
-
21.5M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
17.5M
-
Shares change
-
+3.62M
-
Total reported value, excl. options
-
$205M
-
Value change
-
+$48.6M
-
Number of buys
-
32
-
Number of sells
-
-38
-
Price
-
$11.75
Significant Holders of Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) as of Q3 2025
82 filings reported holding CTNM - Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share as of Q3 2025.
Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.5M shares
of 21.5M outstanding shares and own 81.29% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (2.12M shares), JOHNSON & JOHNSON (1.98M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.72M shares), FRANKLIN RESOURCES INC (1.66M shares), VANGUARD GROUP INC (964K shares), Balyasny Asset Management L.P. (951K shares), FMR LLC (815K shares), SECTORAL ASSET MANAGEMENT INC (801K shares), PERCEPTIVE ADVISORS LLC (715K shares), and HHLR ADVISORS, LTD. (669K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.